OncoPharm podcast

Paradigm and Daraxonrasib in NSCLC

9/3/2026
0:00
14:31
Rewind 15 seconds
Fast Forward 15 seconds
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

More episodes from "OncoPharm"